Hyogo, Japan

Shohei Egawa


Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 1988-1990

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Shohei Egawa

Introduction

Shohei Egawa is a prominent inventor based in Hyogo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for skin conditions. With a total of 4 patents to his name, Egawa's work reflects a commitment to advancing medical science and improving patient care.

Latest Patents

Egawa's latest patents include a pharmaceutical preparation for tinea pedis, which is designed to treat athlete's foot. This preparation contains about 0.1% to about 2.5% of croconazole hydrochloride and about 1% to 15% of an ethyl acrylate-methyl methacrylate copolymer in an aqueous alcohol. Additionally, he has developed an external preparation of vitamin E, consisting of about 0.1% to about 5% of tocopherol acetate and/or about 0.05% to about 0.3% of glycyrrhetinic acid. This formulation also includes a methacrylic acid-ethyl acrylate copolymer and a thickening agent in an alcoholic solvent.

Career Highlights

Egawa is currently associated with Shionogi Company Limited, a well-respected pharmaceutical company. His work at Shionogi has allowed him to focus on innovative solutions for dermatological issues, contributing to the company's reputation for excellence in pharmaceutical development.

Collaborations

Throughout his career, Egawa has collaborated with notable colleagues, including Izumi Saitoh and Yoshio Doi. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmaceuticals.

Conclusion

Shohei Egawa's contributions to pharmaceutical innovation demonstrate his dedication to improving health outcomes through research and development. His patents reflect a deep understanding of medical needs and a commitment to addressing them effectively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…